GOSS 2.98 ▲ 7.58% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Gossamer Bio Inc.

    NASDAQ: GOSS · Real-Time Price · USD
    2.98
    0.21 (7.58%)
    At close: Sep 10, 2025, 11:27 AM
    7.58%
    Bid 2.97
    Market Cap 677.6M
    Revenue (ttm) 40.24M
    Net Income (ttm) -138.74M
    EPS (ttm) -0.61
    PE Ratio (ttm) -4.89
    Forward PE -5.54
    Analyst Buy
    Ask 2.98
    Volume 6,427,961
    Avg. Volume (20D) 3,182,772
    Open 2.99
    Previous Close 2.77
    Day's Range 2.94 - 3.40
    52-Week Range 0.66 - 3.40
    Beta 1.95

    About GOSS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GOSS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GOSS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Gossamer Bio Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 hours ago
    Gossamer Bio shares are trading higher after UBS u... Unlock content with Pro Subscription
    1 month ago
    -8.33%
    Gossamer shares are trading lower. The company reported Q2 financial results.
    news image

    19 hours ago · seekingalpha.com

    Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

    GOSS's Seralutinib remains its main value driver. This is an inhaled TKI for PAH and PH-ILD. Seralutinib's PROSERA Phase 3 trial is now fully enrolled with 6MWD as its primary endpoint. We should get ...

    news image

    1 week ago · businesswire.com

    Gossamer Bio to Present at Upcoming Investor Conferences

    SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...

    news image

    1 month ago · businesswire.com

    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...

    news image

    1 month ago · zacks.com

    Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

    Gossamer Bio (GOSS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.22 per share a year ago.

    news image

    1 month ago · businesswire.com

    Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

    SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...

    news image

    2 months ago · businesswire.com

    Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

    SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...

    news image

    3 months ago · https://www.defenseworld.net

    Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS)

    Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutiona...

    Add to Watchlist